A big misunderstanding
9 January 2019
Email
Share
Celgene shareholders will welcome Bristol-Myers Squibb’s $74 bln takeover offer. The acquirer’s owners might eventually gain too. But such mega-deals distract managers and rarely serve workers or the common good. If corporate purpose was better and broader, they would be scarce.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.